Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer

被引：0

作者：

Chen, X. ^{[1
]}

Zhang, H. ^{[1
]}

Li, Y. ^{[1
]}

Liu, L. ^{[1
]}

Qu, X. ^{[1
]}

机构：

[1] Guangzhou Univ Tradit Chinese, Guangzhou, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

Small Cell Lung Cancer; Immune checkpoint inhibitors; Efficacy and Safety;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP14.01-00

引用

页码：S527 / S527

页数：1

共 50 条

[31] Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease [J].

Fujimoto, Daichi ;

Shimizu, Ryoko ;

Kato, Ryoji ;

Sato, Yuki ;

Kogo, Mariko ;

Ito, Jiro ;

Teraoka, Shunsuke ;

Otoshi, Takehiro ;

Nagata, Kazuma ;

Nakagawa, Atsushi ;

Otsuka, Kojiro ;

Katakami, Nobuyuki ;

Tomii, Keisuke .

ANTICANCER RESEARCH, 2015, 35 (11) :6261-6266

[32] EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study [J].

Ganti, A. K. ;

Allan, V. ;

Merola, D. ;

Estrin, A. ;

Boccuti, A. ;

Rengarajan, B. ;

Baratta, C. ;

Prince, P. ;

Li, W. ;

Cao, Y. ;

D'Agostino, R. B., Jr. ;

Poole, E. M. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S378-S379

[33] Small cell lung cancer (CPC) - Second line treatment [J].

Leheau, B. .

REVUE DES MALADIES RESPIRATOIRES, 2006, 23 (05) :S205-S208

[34] Efficacy of Chemotherapy in Small Cell Lung Cancer: Second Line and Beyond [J].

Ozturk, B. ;

Bayram, S. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S1026-S1026

[35] Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer [J].

Chen, T. ;

Jiang, J. ;

Wang, M. ;

Hu, X. ;

Shi, Y. ;

Liu, Y. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S711-S711

[36] Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 [J].

Spigel, D. R. ;

Vicente, D. ;

Ciuleanu, T. E. ;

Gettinger, S. ;

Peters, S. ;

Horn, L. ;

Audigier-Valette, C. ;

Pardo Aranda, N. ;

Juan-Vidal, O. ;

Cheng, Y. ;

Zhang, H. ;

Shi, M. ;

Luft, A. ;

Wolf, J. ;

Antonia, S. ;

Nakagawa, K. ;

Fairchild, J. ;

Baudelet, C. ;

Pandya, D. ;

Doshi, P. ;

Chang, H. ;

Reck, M. .

ANNALS OF ONCOLOGY, 2021, 32 (05) :631-641

[37] Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer [J].

Froeschl, Sandra ;

Nicholas, Garth ;

Gallant, Victor ;

Laurie, Scott A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) :163-169

[38] Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer [J].

Hanvesakul, Raj ;

Rengarajan, Badri ;

Naveh, Navit ;

Boccuti, Anne ;

Park, Julie E. ;

Adeyemi, Adekemi ;

Caisip, Clyde ;

Jansen, Jeroen P. ;

Wilson, Florence R. .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (05)

[39] Ambamustine in the second-line treatment of patients with small-cell lung cancer - A phase II Fonicap study [J].

Ardizzoni, A ;

Antonelli, G ;

Ricci, S ;

Frasci, G ;

Rinaldi, M ;

Boni, L ;

Galletti, P ;

Pennucci, MC ;

Antonuzzo, A ;

Gravina, A ;

Galli, L ;

Comella, G ;

Conte, PF ;

Salvati, F ;

Rosso, R .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01) :22-25

[40] Which chemotherapy regimen might be the best for the second-line treatment of patients with small-cell lung cancer? [J].

Yildiz, Oguzhan ;

Karaagac, Mustafa ;

Eryilmaz, Melek Karakurt ;

Artac, Mehmet .

ONCOLOGY IN CLINICAL PRACTICE, 2021, 17 (06) :244-252

← 1 2 3 4 5 →